Gamma-aminobutyric acid type A receptor alpha-1 beta-gamma-2 subtype (GABA_A receptor α1βγ2) (GABA_A receptor α1βγ2)

The Gamma-aminobutyric acid type A (GABA_A) receptor alpha-1 beta-gamma-2 subtype is the most prevalent inhibitory neurotransmitter receptor in the mammalian central nervous system (Olsen & Sieghart, 2008). It is a heteropentameric ligand-gated ion channel that mediates fast inhibitory postsynaptic potentials by allowing chloride ions to flow into the neuron, leading to hyperpolarization (Sigel & Steinmann, 2012). This specific subtype is defined by the presence of the alpha-1 subunit, which confers high sensitivity to classical benzodiazepines and certain "Z-drugs" like zolpidem (Rudolph & Knoflach, 2011). These drugs act as positive allosteric modulators at the interface of the alpha-1 and gamma-2 subunits, enhancing the receptor's response to endogenous GABA (Goetz et al., 2007). Clinically, this receptor is a primary target for treating anxiety, insomnia, and seizure disorders due to its potent sedative and anticonvulsant effects (Nutt & Malizia, 2001). However, long-term pharmacological modulation is associated with significant challenges, including the development of tolerance, physical dependence, and potential for respiratory depression (StatPearls, 2023). The alpha-1 subunit specifically is often associated with the sedative and amnestic effects of benzodiazepines, while other subunits mediate anxiolytic effects (Rudolph & Knoflach, 2011). Understanding the precise stoichiometry and distribution of this subtype is essential for developing more selective pharmacological agents with fewer side effects (Olsen & Sieghart, 2008).

Other names

GABRA1-GABRB-GABRG2 receptorBenzodiazepine-sensitive GABA-A receptorα1-containing GABA-A receptorGABA(A) receptor alpha1 subunit-containing complex

Positive allosteric modulation at the benzodiazepine binding site (alpha-1/gamma-2 interface) to increase chloride channel opening frequency (Sigel & Steinmann, 2012).